Not recruitingRare disease

Study on Bevacizumab Injections for Patients with Coats' Disease

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a rare eye condition called Coats' disease. This disease affects the blood vessels in the retina, which is the light-sensitive layer at the back of the eye, and can lead to vision problems. The study is investigating the use of a treatment called Avastin, which contains the active substance bevacizumab. Avastin is given as an injection directly into the eye, a method known as intravitreal injection. The purpose of the study is to compare the effectiveness of Avastin with a standard treatment called laser photocoagulation, which uses a laser to seal off abnormal blood vessels in the eye.

Participants in the study will receive either the Avastin injections or the laser treatment. The study will last for about six months, during which the progress of the disease will be monitored. The main goal is to see if Avastin can improve the condition of the eye by at least one stage, according to a specific classification system used by eye doctors. The study will also look at other factors, such as changes in vision and the thickness of the retina, to understand the overall impact of the treatment.

Throughout the study, participants will have regular check-ups to assess their eye health and any changes in their condition. The study aims to provide valuable information on whether Avastin can be a beneficial treatment option for people with Coats' disease, potentially offering an alternative to the current standard treatment. This research could help improve the management of this rare eye condition and enhance the quality of life for those affected by it.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial treatment phase
The study begins with the administration of an intravitreal injection of bevacizumab (Avastin®). This medication is injected directly into the eye to treat Coats' disease.
The injection is given as a solution for infusion, specifically designed for use inside the eye.
Step 2
Follow-up and monitoring
After the initial treatment, the condition of the eye is monitored at regular intervals. Evaluations occur at 2, 4, 6, and 9 months after the start of the treatment.
These evaluations include checking for improvements in the disease stage, visual acuity, and other eye health indicators using various imaging techniques.
Step 3
Comparison of treatment outcomes
The study compares the effects of the bevacizumab injection with a reference treatment, which involves laser photocoagulation. This comparison helps determine the effectiveness of the injection.
The primary goal is to see if there is an improvement in the disease stage 6 months after treatment begins.
Step 4
Additional treatment assessment
If necessary, additional treatments may be considered. This could include more laser sessions or surgical interventions, depending on the patient's response to the initial treatment.
The need for further treatment is assessed 9 months after the initial treatment.
Step 5
Final evaluation
The final evaluation of the treatment's effectiveness and any side effects is conducted at the end of the study period.
This includes a comprehensive assessment of the eye's condition and any changes in the disease stage.

Who can join the trial?

6 criteria

The patient must be **16 years old or younger**.
The patient must have **Coats' disease**, which is confirmed by a special eye exam called a **fundus examination** and a test called **fluorescein angiography**. This test uses a dye to look at the blood vessels in the eye.
The disease must be at **Stage 2 or 3** according to a specific way of classifying the disease, known as the **Shields classification**.
The patient must not have received any previous treatment for the eye affected by Coats' disease. This means the eye is **naïve to any ocular treatment**.
The patient must be a **beneficiary of a Social Security scheme**. This means they should be covered by a health insurance plan.
Both parents or guardians must provide **free, informed, written consent** for the patient to participate in the study. This means they agree to the study after understanding all the details.

Who cannot join the trial?

6 criteria

Patients who have any other eye disease besides Coats' disease cannot participate. Coats' disease is a rare eye condition that affects the blood vessels in the retina.
Patients who have had previous eye surgery or treatment for Coats' disease are not eligible.
Patients with a history of severe allergic reactions to medications used in the study cannot join.
Patients with any serious health condition that might interfere with the study treatment are excluded.
Pregnant or breastfeeding women are not allowed to participate.
Patients who are unable to follow the study procedures or attend follow-up visits are not eligible.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Centre Hospitalier Universitaire De Bordeaux
Verified
Bordeaux, France
Centre Hospitalier Universitaire Reims
Verified
Reims, France
Fondation A De Rothschild
Verified
Paris, France

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Bevacizumab (Avastin)
is a medication used in this trial as an initial and then additional treatment for Coats' disease. It is given through an injection into the eye. Bevacizumab works by blocking a protein called VEGF, which can help reduce abnormal blood vessel growth and leakage in the eye, potentially improving vision or preventing further vision loss.
Laser Photocoagulation
is a reference treatment used in this trial for Coats' disease. This therapy involves using a laser to seal or destroy abnormal blood vessels in the eye. The goal is to prevent these vessels from leaking fluid or blood, which can help stabilize or improve vision.

Bevacizumab

What is already known about the treatment

Bevacizumab (Avastin) – This medication is administered through an injection directly into the eye, known as an intravitreal injection. It is currently being studied in clinical trials for its effectiveness in treating Coats' disease, a rare eye disorder. Bevacizumab works by inhibiting a protein called vascular endothelial growth factor (VEGF), which plays a role in the formation of abnormal blood vessels. It is classified as an anti-VEGF agent and is commonly used to treat various eye conditions involving abnormal blood vessel growth.

Investigated diseases

Coats' disease – Coats' disease is a rare eye condition characterized by abnormal development of blood vessels in the retina, leading to leakage of blood and fluid. This leakage can cause retinal swelling and detachment, potentially affecting vision. The disease typically progresses through stages, starting with mild symptoms like small retinal telangiectasia and advancing to more severe stages with significant exudation and retinal detachment. It primarily affects young males and is usually unilateral, meaning it affects only one eye. As the disease progresses, it can lead to complications such as glaucoma or phthisis bulbi, where the eye becomes shrunken and non-functional. Early detection and monitoring are crucial to managing the progression and preserving vision.